The Inhibitory Activity of Curcumin on P-Glycoprotein and Its Uptake by and Efflux from LS180 Cells Is Not Affected by Its Galenic Formulation

The biological activities of curcumin in humans, including its antioxidative and anti-inflammatory functions, are limited by its naturally low bioavailability. Different formulation strategies have been developed, but the uptake of curcumin from these galenic formulations into and efflux from intest...

Full description

Saved in:
Bibliographic Details
Main Authors: Sandra Flory (Author), Romina Männle (Author), Jan Frank (Author)
Format: Book
Published: MDPI AG, 2021-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9b59b5d958a942fb8b64a7833c65a9c4
042 |a dc 
100 1 0 |a Sandra Flory  |e author 
700 1 0 |a Romina Männle  |e author 
700 1 0 |a Jan Frank  |e author 
245 0 0 |a The Inhibitory Activity of Curcumin on P-Glycoprotein and Its Uptake by and Efflux from LS180 Cells Is Not Affected by Its Galenic Formulation 
260 |b MDPI AG,   |c 2021-11-01T00:00:00Z. 
500 |a 10.3390/antiox10111826 
500 |a 2076-3921 
520 |a The biological activities of curcumin in humans, including its antioxidative and anti-inflammatory functions, are limited by its naturally low bioavailability. Different formulation strategies have been developed, but the uptake of curcumin from these galenic formulations into and efflux from intestinal cells, which may be critical processes limiting bioavailability, have not been directly compared. Furthermore, little is known about their effect on P-glycoprotein activity, an important determinant of the pharmacokinetics of potentially co-administered drugs. P-glycoprotein activity was determined in LS180 cells, incubated with 30 or 60 µmol/L of curcumin in the form of seven different formulations or native curcuma extract for 1 h. All formulations inhibited P-glycoprotein activity at both concentrations. Curcumin uptake, after 1 h incubation of LS180 cells with the formulations (60 µmol/L), showed significant variability but no consistent effects. After 1 h pre-treatment with the formulations and further 8 h with curcumin-free medium, curcumin in cell culture supernatants, reflecting the efflux, differed between individual formulations, again without a clear effect. In conclusion, curcumin inhibits P-glycoprotein activity independently of its formulation. Its uptake by and efflux from intestinal cells was not significantly different between formulations, indicating that these processes are not important regulatory points for its bioavailability. 
546 |a EN 
690 |a cellular uptake 
690 |a curcuminoids 
690 |a cyclodextrin complex 
690 |a drug interactions 
690 |a efflux transporter 
690 |a intestinal cell line 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antioxidants, Vol 10, Iss 11, p 1826 (2021) 
787 0 |n https://www.mdpi.com/2076-3921/10/11/1826 
787 0 |n https://doaj.org/toc/2076-3921 
856 4 1 |u https://doaj.org/article/9b59b5d958a942fb8b64a7833c65a9c4  |z Connect to this object online.